Top Page
Lepu Biopharma Co. Ltd. Class H
(2157)
Lepu Biopharma Co. Ltd. Class H (2157) vs. iShares MSCI Hong Kong ETF (EWH)
Lepu Biopharma Co. Ltd. Class H Business Overview & Revenue Model
Lepu Biopharma Co. Ltd. Class H Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 367.79M | 225.35M | 15.57M | 0.00 | 0.00 |
| Gross Profit | 292.97M | 197.07M | 13.57M | 0.00 | 0.00 |
| EBITDA | -311.94M | 86.95M | -596.53M | -865.23M | -371.01M |
| Net Income | -411.38M | -22.10M | -689.05M | -1.01B | -581.85M |
Balance Sheet | |||||
| Total Assets | 2.28B | 2.38B | 2.53B | 2.08B | 2.42B |
| Cash, Cash Equivalents and Short-Term Investments | 464.91M | 498.43M | 669.40M | 205.17M | 753.52M |
| Total Debt | 850.16M | 746.82M | 690.30M | 335.26M | 203.08M |
| Total Liabilities | 1.60B | 1.50B | 1.63B | 1.23B | 921.89M |
| Stockholders Equity | 702.83M | 896.90M | 900.76M | 836.71M | 1.47B |
Cash Flow | |||||
| Free Cash Flow | -258.14M | -292.04M | -591.38M | -835.12M | -724.51M |
| Operating Cash Flow | -196.39M | -250.84M | -480.93M | -621.74M | -422.69M |
| Investing Cash Flow | -61.75M | 18.26M | -74.66M | -3.89M | -749.67M |
| Financing Cash Flow | 232.08M | -11.01M | 1.03B | 380.31M | 1.39B |
Lepu Biopharma Co. Ltd. Class H Technical Analysis
Lepu Biopharma Co. Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$10.64B | 290.36 | 4.16% | ― | 34.39% | ― | |
57 Neutral | HK$17.75B | ― | -51.40% | ― | 58.75% | -1310.16% | |
55 Neutral | HK$19.54B | ― | -18.87% | ― | 16.35% | -49.63% | |
53 Neutral | HK$11.56B | ― | -13.97% | ― | -97.81% | -117.20% | |
53 Neutral | HK$12.47B | ― | -55.68% | ― | ― | -4.33% | |
51 Neutral | $7.38B | 0.42 | -62.86% | 2.37% | 15.61% | -1.95% | |
45 Neutral | HK$8.69B | ― | -44.39% | ― | 18989.90% | 18.84% |
Lepu Biopharma Co. Ltd. Class H Corporate Events
Lepu Biopharma Co., Ltd. announced a positive profit alert, expecting a profit of not less than RMB24 million for the first half of 2025, marking a significant turnaround from a loss of approximately RMB197.0 million in the same period of 2024. This improvement is attributed to substantial revenue growth driven by increased sales of PUYOUHENG and income from a licensing collaboration with ArriVent BioPharma, Inc. The announcement indicates a strong operational performance and potential positive implications for stakeholders, although the results are preliminary and subject to finalization.
Lepu Biopharma Co., Ltd. has announced that its board of directors will hold a meeting on August 20, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The board will also consider recommending the payment of an interim dividend and address other business matters. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and potential dividend payouts, which could impact investor confidence and market positioning.
Lepu Biopharma Co., Ltd. announced a significant licensing transaction with Excalipoint, granting them exclusive rights to develop and commercialize two pre-clinical assets worldwide. This strategic move is part of Lepu Biopharma’s long-term strategy to globalize its pipeline and technologies, allowing the company to focus on advancing its research priorities and accelerating the commercialization of late-stage products. The deal includes an upfront payment of $10 million, potential milestone payments up to $847.5 million, and sales royalties. Additionally, Excalipoint will conduct a series A financing round, raising $41 million, which complements the licensing transaction and supports the company’s growth strategy.
Lepu Biopharma Co., Ltd. has successfully completed the conversion of 54,268,364 unlisted shares into H shares, marking the completion of its H share full circulation. This strategic move enhances the company’s market presence by increasing the liquidity of its shares, as the converted H shares will be listed on the Stock Exchange starting July 22, 2025. The company’s share capital structure now consists entirely of H shares, which could potentially attract more investors and improve stakeholder confidence.
Lepu Biopharma Co. Ltd. has successfully completed the placing of 93,825,000 new H shares, raising approximately HK$462.94 million in net proceeds. The funds will be allocated towards the commercialization and marketing of MRG003, advancing clinical trials of core products, and research and development of new product pipelines. This strategic move increases the company’s total issued shares and strengthens its financial position to enhance its market presence in the oncology sector.
Lepu Biopharma Co. Ltd. has announced a placement agreement to issue up to 93,825,000 new H shares at a price of HK$5.02 per share, aiming to raise approximately HK$462.94 million. This strategic move is expected to enhance the company’s capital base and support its growth initiatives, although the completion of the placement is contingent upon certain conditions being met.
Lepu Biopharma Co., Ltd. has established a Nomination Committee under its board of directors to enhance corporate governance by regulating the appointment of directors and senior management. This move aims to optimize the board’s composition and improve governance structures, potentially impacting the company’s operational efficiency and strategic direction.
Lepu Biopharma Co., Ltd. successfully held its 2024 Annual General Meeting (AGM) on June 27, 2025, where all proposed resolutions were approved by shareholders. The resolutions included approval of financial reports, profit distribution plans, and the re-appointment of Ernst & Young as auditors, reflecting strong shareholder support and strategic alignment for the company’s future operations.
Lepu Biopharma Co., Ltd. announced a change in the composition of its Nomination Committee, with Dr. Pu Zhongjie stepping down and Ms. Pu Jue being appointed as a new member. This change aligns with upcoming amendments to the Listing Rules and Corporate Governance Code, effective July 1, 2025, aimed at enhancing the effectiveness, diversity, and governance practices of the company’s board.
Lepu Biopharma Co., Ltd. has received approval from the Hong Kong Stock Exchange for the listing of 54,268,364 H shares, marking a significant step in its conversion and listing process. This approval allows the company to convert its unlisted shares, held by four main stakeholders, into H shares, which will now represent approximately 3.17% of the company’s total issued shares. This move is expected to enhance the company’s market presence and provide greater liquidity for its shares.
Lepu Biopharma Co., Ltd. has announced its 2024 Annual General Meeting (AGM) scheduled for June 27, 2025, in Hong Kong. The meeting will address several key resolutions, including the approval of the 2024 annual report, financial accounts, and profit distribution plan, as well as the re-appointment of Ernst & Young as auditors. The AGM will also consider granting the Board a mandate to issue additional shares, which could impact the company’s strategic initiatives and shareholder value.
Lepu Biopharma Co., Ltd. announced the resignation of Mr. Yang Hongbing from his position as a non-executive director due to personal and professional commitments. The board expressed gratitude for his contributions and proposed the appointment of Ms. Qin Yiran as his successor, pending shareholder approval at the upcoming annual general meeting. Ms. Qin, currently an investment director at Hainan Shiyu Private Equity Management Co., Ltd., brings a strong background in biology and investment management to the role, potentially enhancing the company’s strategic direction.
Lepu Biopharma Co., Ltd. announced the presentation of pivotal clinical trial results for its drug candidate MRG003 at the 2025 ASCO Annual Meeting. MRG003, an innovative ADC targeting epidermal growth factor receptor, showed significant improvements in objective response rate and progression-free survival compared to chemotherapy in patients with recurrent or metastatic nasopharyngeal cancer. The study suggests a potential paradigm shift in treatment, demonstrating meaningful benefits while maintaining a manageable safety profile.
Lepu Biopharma Co., Ltd. has announced that it received a filing notice from the China Securities Regulatory Commission (CSRC) regarding its application for the full circulation of H shares. This development involves converting 54,268,364 unlisted domestic shares into H shares for listing on the Hong Kong Stock Exchange. While the CSRC filing has been completed, the company must still fulfill additional procedures required by relevant regulatory authorities. The announcement indicates potential changes in the company’s share structure and market presence, advising shareholders and investors to exercise caution.